Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 4Oligodendroglioma 2Astrocytoma 2Recurrence 1Pathologic Processes 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasms 1Healthy Adult Participants 1Disease Attributes 1

Interventions

Temozolomide 4Flucytosine 4vocimagene amiretrorepvec 3vorasidenib 2trametinib 2paclitaxel-Angiopep-2 conjugate 2dabrafenib 2Surgical Procedures, Operative 2OKN 007 2Chlorotoxin 2Carmustine 2talampanel 1selinexor 1pemigatinib 1pembrolizumab 1olutasidenib 1motexafin gadolinium 1exatecan 1Vincristine 1Radiation 1PF-06840003 1ONC206 1O(6)-benzylguanine 1Metabolism 1IL13-PE38 1Genetic Therapy 1Genetic Engineering 1Filgrastim 1Fentanyl 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Oligodendroglioma × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡